LEUVEN, Belgium, October 21, 2013 -- /PRNewswire/ --
ThromboGenics NV (Euronext Brussels: THR) a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today that JETREA® (ocriplasmin) is nominated for the 2013 Prix Galien USA Award in the Best Biotechnology Product category.
The Prix Galien USA, now in its seventh year, is an international award that recognizes outstanding achievements in improving human health through the development of innovative therapies. The winner is selected by a committee of nine experts in the biomedical industry and academia, including five Nobel Laureates.
JETREA® is the first and only pharmacological drug approved by the US Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (VMA). ThromboGenics launched the drug in the US in mid-January 2013. The Company employs 100 people in the US, including 35 operating from its US office in Iselin, New Jersey.
JETREA® was approved in the European Union in March 2013. Partner Alcon, a division of Novartis, launched the drug in the UK, its first market in Europe, in April, and is rolling out the drug across Europe. Alcon acquired the rights to commercialize JETREA® outside the United States in March 2012.
Help employers find you! Check out all the jobs and post your resume.
